Article Information
History
- March 9, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- BJM Bergmans1,2,*,
- BY Gebeyehu1,3,
- EP van Puijenbroek4,5,
- K Van Deun3,
- B Kleinberg3,
- JL Murk2,6 and
- E de Vries1,2
- 1Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands
- 2Department of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands
- 3Department of Methodology and Statistics, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands
- 4Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands
- 5University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, - Epidemiology & -Economics, Groningen, The Netherlands
- 6Microvida, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands
- ↵*Corresponding author b.j.m.bergmans{at}tilburguniversity.edu Postbus 90153, 5000 LE Tilburg
Posted March 09, 2023.
Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis
